although some controversy remains. Islets exposed to sustained hyperglycaemia have shown impaired in beta-cell function [11] [12] [13] , limited replicative response, and reduced beta-cell mass [14] . In addition, hyperglycaemia reduced blood perfusion and delayed revascularization of the graft in several, but not all, studies [15] [16] [17] . Thus, it might be expected that normoglycaemia would improve the prognosis of islet transplantation, and a beneficial effect of insulin treatment has been reported [18, 19] . However, the protection of islets by insulin treatment has been considered unnecessary in other studies [20] . The reasons for the potential benefit of insulin treatment have not been generally addressed, and in particular little is known about its effect on transplanted beta-cell mass. The aim of this study was to determine whether insulin treatment may improve the success of islet transplantation, and to analyse its effects on the function and mass of transplanted beta cells.
Materials and methods
Male inbred C57Bl/6 mice (B&K Universal, Humberside, UK) aged 7 to 10 weeks, were used as donors and recipients of transplantation. The recipients were made diabetic by a single intraperitoneal injection of streptozotocin (STZ) (Streptozotocin; Sigma Immunochemicals, St. Louis, Mo. USA) 180 mg/ kg body weight, freshly dissolved in citrate buffer (pH = 4.5). Before transplantation, diabetes was confirmed by hyperglycaemia, weight loss, and polyuria. Only those mice with a blood glucose level higher that 20 mmol/l were given a transplant. Blood glucose was determined between 09.00 and 11.00 hours under non-fasting conditions, unless stated otherwise. Blood was obtained from the snipped tail with a heparinized microcapillary tube and glucose was measured with a portable glucose meter (Reflolux II; Boehringer-Mannheim Biochemicals, Mannheim, Germany). Animals were kept under conventional conditions in climatized rooms with free access to tap water and standard pelleted food.
Animal groups. Four groups of STZ-diabetic mice were transplanted with 100 syngeneic islets, which is an insufficient beta-cell mass to restore normoglycaemia [17, 21] . Mice were randomly distributed among the four groups. When diabetes was confirmed, 4 to 10 days after STZ injection, groups 1 (n = 12) and 2 (n = 12) were started on insulin, and groups 3 (n = 12) and 4 (n = 18) were transplanted. Groups 1 and 2 were subsequently transplanted, after 10-14 days of insulin treatment and a minimum of 6 days of normoglycaemia (blood glucose below 10.0 mmol/l). The insulin implants were removed 14 days after transplantation, after a total of 24-28 days of insulin treatment. The grafts were harvested 14 (groups 1 and 3) or 60 (groups 2 and 4) days after transplantation.
A control group (n = 6) of normal non-transplanted mice had their blood glucose and body weight determined weekly. In addition, a group of STZ-diabetic mice (n = 4) was treated with insulin for 28 days, but was not transplanted. The initially transplanted beta-cell mass was determined in 8 groups of 100 isolated islets, and the insulin content was measured in 7 groups of 100 isolated islets.
Insulin treatment. Groups 1 and 2 were treated with sustained release insulin implants (LinBits; Linshin Canada, Inc., Scarborough, Canada). The implants are made of a compressed admixture of bovine insulin and microrecrystallized palmitic acid allowing a sustained release of insulin that achieves a more constant blood glucose level than insulin injections. Under light ether anaesthesia two insulin implants were placed subcutaneously in the nape of the neck; in all animals the implants were easily identified and removed in a single piece. Two mice died during insulin treatment, probably because of hypoglycaemia, and were not included in the study. To ensure that stable normoglycaemia had been achieved, blood glucose was determined twice every 2 days during the last 6 days before transplantation (between 09.00 and 11.00 hours and between 15.00 and 17.00 hours). After transplantation blood glucose was determined once every 2 days until day 14 after transplantation, when insulin treatment was discontinued, and twice weekly until the completion of the study.
Islet isolation and transplantation. Islets were isolated by collagenase (Collagenase P; Boehringer Mannheim Biochemicals) digestion of the pancreas as previously described [14] . Isolated islets were hand-picked under a stereomicroscope two or three times until a population of pure islets was obtained. Only those islets over 75 and under 250 m m in diameter were collected and counted into groups of 100 islets that were transplanted under the left kidney capsule of the recipient on the day of the isolation [22] . After transplantation, the capsulotomy was cauterized with a disposable low-temperature cautery pen (F. L. Fischer Bipolator, Berlin, Germany) and the lumbar incision was sutured.
Graft and pancreas harvesting. Six hours before graft harvesting, mice were injected with 5-bromo-2′deoxyuridine (BrdU) (Sigma Immunochemicals) 100 mg/kg body weight IP, to determine beta-cell replication. To harvest the graft, the kidney was exposed with the mouse under light ether anaesthesia. The graft was identified as a white patch in normoglycaemic mice, and a more translucent graft was found in hyperglycaemic mice. The kidney capsule surrounding the graft was incised and removed with the graft. All normoglycaemic mice became hyperglycaemic after graft harvesting. In control mice, animals were injected with BrdU 6 h before pancreas excision.
Immunocytochemistry. After removal, the graft was immediately immersed in Bouin's fixative. Then any excess of Bouin's was carefully removed by capillary action and the weight of the graft was determined on a Mettler balance type A240 reading to 0.01 mg (Mettler Instruments Corporation, Hightstown, NJ USA) and processed for paraffin embedding. Sections of 2mm were double stained with immunoperoxidase for BrdU (Cell Proliferation Kit, Amersham International, Amersham, UK), and for the endocrine non-beta cells of the islets. To stain the endocrine non-beta cells we used a cocktail of antibodies (Dako Corporation, Carpinteria, Calif., USA) anti-glucagon, -somatostatin, and -pancreatic polypeptide [22] . The sections were stained with 3,3′-diaminobenzimide tetrahydrochloride (Sigma Immunochemicals) and hydrogen peroxide (Merck, Darmstadt, Germany). We stained the endocrine non-beta cells instead of the beta cells because chronic hyperglycaemia, expected in groups 3 and 4, is associated with beta-cell degranulation resulting in weak or negative staining of beta cells. In addition, BrdU positive beta cells, with stained cytosol and nucleus, would have been difficult to discern.
Beta-cell replication, individual beta-cell area, and beta and non-beta-cell mass.
Methods used for measurement of beta-cell replication, area and mass have been described in detail [14, 22] . After immunoperoxidase staining, beta cells and BrdU positive beta cells were counted using on Olympus BH-2 microscope connected to a video camera with a colour monitor. Results were expressed as percentage of BrdU positive beta cells after counting at least 1200 cells per graft.
The mean cross-sectional area of individual beta cells, a measure of beta cell size, was determined on immunoperoxidase stained sections of grafts and isolated islets with an electronic planimetry program (Sigma Scan 3.9; Jandel Scientific, Erkrath, Germany). As pointed out previously, not all beta cells were sectioned across their nuclei and therefore the size of beta cells was overestimated, although to a lesser extent than in previous experiments using 1 m m sections [14] . Beta-cell mass was measured by point counting morphometry on immunoperoxidase stained sections of grafts using a 48-point grid to obtain the number of intercepts over betacells, over endocrine non-beta cells and over other tissue. The beta-cell mass of islets at the time of transplantation was determined in eight groups of 100 islets isolated on different days. After isolation, the islets were washed in phosphate buffered saline and pelleted in Bouin's fixative. Any excess of Bouin's was removed by capillary action and the pellet was weighed. The endocrine non-beta-cell tissue in the grafts was not enough to provide the required number of intercepts needed for a representative sampling [23] , and it was derived from the subtraction of beta-cell mass from the total endocrine mass of the graft.
Intraperitoneal glucose tolerance test (IPGTT).
IPGTTwas performed on days 54-58 after transplantation in all normoglycaemic animals and in control mice of similar age. Between 11.00 hours and noon, after a 2-h fast, non-anaesthetized mice were injected with a 10 % glucose solution (ERN Laboratory, Barcelona, Spain) 1.5 g ⋅ kg −1 ⋅ body weight −1 IP. Blood glucose was determined at the time of injection and 30, 60, 90, 120 and 180 min later. Total area under the curve (AUC) was estimated using the trapezoidal rule method.
Insulin content. The insulin content was determined in five grafts of groups 1, 2 and 3. After harvesting, the grafts were homogenized in 500 m l of acid ethanol and the samples were extracted overnight at 4°C. On the following day they were centrifuged at 2400 rev/min for 10 min and the supernatant was stored at − 20°C until assayed for insulin content. Insulin was measured by radioimmunoassay using a rat insulin standard (Novo Nordisk, Copenhagen, Denmark) and polyethyleneglycol separation. To determine the insulin content in the 7 groups of 100 isolated islets, the islets were homogenized in 500 m l of acid ethanol and processed as described for grafts.
Statistical analysis.
Results are expressed as mean ± SEM. For comparisons between two groups the paired or unpaired Student's t -test, two tailed, was used as appropriate and for multiple comparisons between groups the one-way analysis of variance (ANOVA) was used. When results did not show a normal distribution the Kruskal-Wallis test was used. A p -value of less than 0.05 was considered significant.
Results
Metabolic evolution after transplantation. The characteristics of experimental groups are summarized in Table 1 , and the evolution of blood glucose in shown in Figure 1 . All groups were comparable in age, blood glucose, and body weight when injected with streptozocin as well as when insulin implants were placed (groups 1 and 2) or islets were transplanted (groups 3 and 4). The mean blood glucose value during insulin treatment was lower than that of control mice (insulin treated: 6.7 ± 0.7 mmol/l, control: 7.5 ± 0.2 mmol/l, p < 0.01), although differences were not significant at any time point. Morning and afternoon blood Table 1 . Values are mean ± SEM glucose determinations before transplantation were similar in insulin treated mice (morning: 5.5 ± 0.4 mmol/l, evening: 6.0 ± 0.5 mmol/l) confirming the stability of glucose levels.
All transplanted mice treated with insulin remained normoglycaemic when insulin was discontinued, and normoglycaemia was maintained until the end of the 2-month follow up. In contrast, in non-insulin-treated groups, all mice were hyperglycaemic 14 days after transplantation and only 6 (33 %) were normoglycaemic by day 60. These 6 mice (group 4 a) became normoglycaemic 24-51 (35 ± 4) days after transplantation, and have been analysed separately from the remaining 12 mice with persistent severe hyperglycaemia (group 4). Of these 12 mice, 5 died 9-40 (22 ± 6) days after transplantation due to the severity of diabetes, and transitory insulin treatment (4-7 days) was given between day 40 and 54 to 3 more mice to alleviate their severe metabolic condition. No differences were found between groups 4 and 4 a that could predict the metabolic evolution after transplantation. Hyperglycaemia (> 20 mmol/l) recurred in all normoglycaemic mice when the graft was harvested. The group of diabetic mice treated with insulin but not transplanted, was again severely hyperglycaemic when the insulin implants were removed, further excluding any substantial beta-cell regeneration in the pancreas.
Intraperitoneal glucose tolerance test. Glucose levels were similar in control and group 2 mice (Fig. 2) . In contrast, group 4 a, normoglycaemic but non-treated with insulin, showed a higher glucose peak than control group (control group: 16.0 ± 0.6 mmol/l; group 4 a: 22.4 ± 1.8 mmol/l, p < 0.01) and group 2 (group 2: 18.1 ± 0.3 mmol/l, p < 0.01). The AUC was higher in group 4 a (3916 ± 135 mmol ⋅ l 
Beta-cell mass and endocrine non-beta-cell mass.
The initially transplanted beta-cell mass (0.22 ± 0.02 mg), was reduced 14 days after transplantation both in insulin-treated (group 1: 0.09 ± 0.01 mg, p < 0.01) and in non-insulin-treated (group 3: 0.14 ± 0.02 mg, p < 0.01) mice (Fig. 3) . When insulin treatment was discontinued, beta-cell mass increased and on day 60 it was similar to the initially transplanted mass (group 2: 0.23 ± 0.04 mg). In contrast, in hyperglycaemic non-insulin-treated mice, beta-cell mass continued to decline and was severely reduced on day 60 (group 4: 0.08 ± 0.02 mg, p < 0.001). On the other hand, in non-insulin-treated mice that achieved normoglycaemia beta-cell mass was similar to the initially transplanted mass (group 4 a: 0.24 ± 0.03 mg).
The endocrine non-beta-cell mass showed similar changes to beta-cell mass 14 days after transplantation when it was reduced in normoglycaemic (group 1: 0.009 ± 0.002 mg) and hyperglycaemic mice (group 3: 0.010 ± 0.002 mg) compared to the initially transplanted non-beta-cell mass (0.020 ± 0.001 mg, p < 0.01). In contrast to the evolution of beta-cell mass, no further changes were found on day 60 either in normoglycaemic (group 2: 0.014 ± 0.003 mg) or in hyperglycaemic (group 4: 0.011 ± 0.003 mg) mice. Table 1 . Values are mean ± SEM. * p < 0.01 between group 4 a and groups 2 and control. AUC was higher in group 4 a compared to control and group 2 (p < 0.05) Table 1 . Isolated islets show the initially transplanted beta and non-beta-cell mass. Values are mean ± SEM. Upper panel: * p < 0.01, group 1 vs isolated islets and group 2; ** p < 0.001 between isolated islets and groups 3 and 4. Lower panel: * p < 0.01 between isolated islets and group 1; ** p < 0.01 between isolated islets and groups 3 and 4 Beta-cell replication. Beta-cell replication in insulintreated groups was similar to that in normal pancreases (group 1: 0.54 ± 0.12 %; group 2: 0.47 ± 0.06 %; pancreas: 0.37 ± 0.08 %) (Fig. 4) . In hyperglycaemic groups beta-cell replication was increased initially, after 14 days of hyperglycaemia (group 3: 1.12 ± 0.15 %, p < 0.01), but not after 60 days of hyperglycaemia (group 4: 0.64 ± 0.10 %). Insulin content. Insulin content of 100 freshly isolated islets was 4.5 ± 0.7 m g ( Table 2 ). Fourteen days after transplantation, insulin content was reduced in the grafts of both insulin-treated and non-insulin-treated mice. However, when insulin content was expressed as a function of the beta-cell mass, it was similar in isolated islets (20.4 ± 3.3 m g/mg) and islets transplanted to insulin-treated mice (group 1: 12.5 ± 2.0 m g/mg), but was still severely reduced in hyperglycaemic, noninsulin-treated mice, (1.0 ± 0.2 m g/mg). Sixty days after transplantation, a normal insulin content was maintained in group 2 normoglycaemic mice.
Discussion
In this study, the outcome of islet transplantation was improved when islets were transplanted to normoglycaemic, insulin-treated, diabetic mice. The transplantation of 100 syngeneic islets was not sufficient to restore normoglycaemia in STZ-diabetic mice, and transplanted islets showed a severe reduction in insulin content and beta-cell mass. In contrast, in insulintreated mice, 100 islets achieved long-term normoglycaemia and normal glucose tolerance, and transplanted beta cells maintained a normal insulin content, indicating overall that beta-cell function was preserved. Furthermore, islets transplanted to insulin-treated recipients were able to increase their beta-cell mass to meet an increased metabolic demand when insulin treatment was discontinued.
Insulin treatment reduced significantly the betacell mass needed to cure diabetes in transplanted mice. Although the minimum islet number which consistently achieves normoglycaemia in STZ-diabetic C57Bl/6 mice is 300 islets [14, 21] , all insulintreated mice were cured with only 100 islets. Maintaining normoglycaemia may require a lower Table 1 . Isolated islets show beta-cell area on transplantation day. Values are mean ± SEM. * p < 0.001 between group 2 and isolated islets and group 1. ** p < 0.001 between isolated islets and groups 3 and 4 beta-cell mass than restoring it [24] , and under several clinical and experimental conditions normoglycaemia has been maintained with just 10-30 % of the normal islet tissue [25] [26] [27] . In insulin-treated mice, transplanted islets had to maintain, but not restore, normoglycaemia. On the other hand, when insulin implants were removed 14 days after transplantation, transplanted islets were already vascularized [28] and able to sense and respond more appropriately to changes in blood glucose than freshly transplanted, and not yet vascularized, islets. Moreover, a linear correlation has been found between insulin content and beta-cell function [29] ; thus, the preserved insulin content of islets transplanted to insulin-treated mice contributed to maintain normoglycaemia when insulin was discontinued. Finally, islets transplanted to insulin-treated mice were able to increase their betacell mass when insulin was withdrawn, and this capacity of beta-cell mass to adapt to changes in functional demand is essential to maintain normoglycaemia, as has been shown after glucose infusion [30] , partial pancreatectomy [31] , or islet transplantation [24] .
The IPGTT performed at the end of follow-up in normoglycaemic mice showed that glucose levels were similar in insulin-treated and control groups. In contrast, the few non-insulin-treated mice that eventually achieved normoglycaemia after transplantation showed an abnormal glucose tolerance, suggesting that beta-cell function was impaired in the islets that had been previously exposed to sustained hyperglycaemia. The abnormal glucose tolerance was not due to differences in beta-cell mass, which was similar in both normoglycaemic groups. Similarly, human islets exposed to prolonged hyperglycaemia after transplantation to diabetic nude mice showed an abnormal insulin response to glucose that was not corrected after 2 weeks of normoglycaemia [13] . Therefore, insulin treatment may have prevented the deleterious effect of hyperglycaemia on transplanted islets. The results provide experimental support for maintaining tight metabolic control for the first days after islet transplantation in diabetic patients.
Normoglycaemia did not prevent an initial reduction in transplanted beta-cell mass in insulin-treated mice. The initial loss of some islet tissue is expected after transplantation due to the transplantation procedure itself, to lack of engraftment or to islet hypoxia [5, 32] . The similar reduction of beta-cell and endocrine non-beta-cell mass 14 days after transplantation points to a process damaging the whole islet cell population. We had found a similar reduction in islets transplanted to normal mice [14] . Under both conditions, beta-cell replication and size did not increase after transplantation, preventing the compensation of the initial beta-cell loss. The reduction in transplanted beta-cell mass may be appropriate because islets transplanted to normoglycaemic recipients, either insulin-treated or normal mice, were not needed to maintain normoglycaemia, and theoretically could even put the recipients at risk for hypoglycaemia. In addition, the occasional hypoglycaemic episode detected in some insulin-treated mice may have accentuated the beta-cell mass reduction, since increased beta-cell death has been found in hypoglycaemic animals [33] . On the other hand, the beneficial effect of normoglycaemia on beta-cell survival recently reported by Davalli et al. [32] in the first days after transplantation, may have palliated the initial beta-cell loss.
When insulin implants were removed, transplanted beta-cell mass increased to maintain normoglycaemia, and by day 60 it was similar to the initially transplanted mass. The results suggest that both beta-cell hyperplasia and hypertrophy contributed to expand beta-cell mass, although only beta-cell size was increased 60 days after transplantation. Betacell hypertrophy was not sufficient to account for the increment in beta-cell mass found on day 60, suggesting that hyperplasia took place after insulin withdrawal. Beta-cell replication was probably increased in the first days after insulin withdrawal, when metabolic demand increased suddenly, and then returned to the basal level, as has been reported in response to moderate transient hyperglycaemia [34] .
In contrast, in hyperglycaemic mice the transplanted beta-cell mass declined progressively, confirming our previous results [14] . Beta-cell replication and size were increased 14 days after transplantation, but despite persistent hyperglycaemia the increased beta-cell size replication was not maintained and beta-cell size did not increase further on day 60. This limited capacity to increase beta-cell size and replication in response to hyperglycaemia probably contributed to the progressive reduction of transplanted beta-cell mass.
In summary, normoglycaemia was achieved in insulin-treated mice with the transplantation of an otherwise insufficient beta-cell mass, and despite the initial reduction in transplanted mass. Islets transplanted to normoglycaemic insulin-treated diabetic mice showed better beta-cell function and preserved insulin content compared with islets exposed to hyperglycaemia, and were able to increase their beta-cell mass to meet an increased metabolic demand. The beneficial effect of insulin treatment on transplanted beta cells supports the maintenance of normoglycaemia in the diabetic recipients of islet transplantation in the days preceding and following transplantation.
